Factors associated with improved survival in patients with wild-type transthyretin amyloid cardiomyopathy on tafamidis therapy

11 May 2026 (15:30 - 16:15)
Organised by: Logo
Congress Presentation Part of: Biomarkers, devices and prognosis of heart failure Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)